Parkinson’s stem cell therapy shows promise in Phase II trial

The Hope Biosciences Research Foundation (HBRF) is planning a Phase III trial of its stem cell therapy following encouraging results in a Phase II study for early to moderate Parkinson’s disease. The allogenic adipose-derived mesenchymal stem cell therapy (HB-adMSC) demonstrated disease-modifying potential, with patients showing significant improvements in motor function compared with placebo.

Efficacy was measured using patient-reported Motor Experiences of Daily Living (MDS-UPDRS Part II) and clinician-rated Motor Function (MDS-UPDRS Part III), with a placebo-adjusted -9.32-point reduction in Part III scores, exceeding the -3.25 minimal clinically important difference.

While detailed safety data has not yet been released, the therapy was reportedly well tolerated. HBRF President Donna Chang highlighted that repeated, consistent treatment may provide sustained motor function benefits. Discussions with the FDA will guide the design of the upcoming Phase III confirmatory trial.

28-12-2025